67 related articles for article (PubMed ID: 14533350)
1. Laboratory analysis of HER-2/neu: search for the optimal testing strategy.
Killeen JL
Hawaii Med J; 2003 Aug; 62(8):173-5. PubMed ID: 14533350
[No Abstract] [Full Text] [Related]
2. Comparison of immunohistochemical and fluorescence in situ hybridization assessment of HER-2 status in routine practice.
Egervari K; Szollosi Z; Nemes Z; Kaczur V
Am J Clin Pathol; 2006 Jan; 125(1):155-6. PubMed ID: 16483004
[No Abstract] [Full Text] [Related]
3. Increased risk of brain metastases in patients with HER-2/neu-positive breast carcinoma.
Altaha R; Crowell E; Hobbs G; Higa G; Abraham J
Cancer; 2005 Feb; 103(3):442-3. PubMed ID: 15578684
[No Abstract] [Full Text] [Related]
4. Comparison of immunohistochemistry by automated cellular imaging system (ACIS) versus fluorescence in-situ hybridization in the evaluation of HER-2/neu expression in primary breast carcinoma.
Tawfik OW; Kimler BF; Davis M; Donahue JK; Persons DL; Fan F; Hagemeister S; Thomas P; Connor C; Jewell W; Fabian CJ
Histopathology; 2006 Feb; 48(3):258-67. PubMed ID: 16430472
[TBL] [Abstract][Full Text] [Related]
5. Human epidermal growth factor receptor 2 testing in breast cancer.
Vang Nielsen K; Jørgensen JT; Schønau A; Øster A
J Clin Oncol; 2007 Sep; 25(25):4020; author reply 4021-3. PubMed ID: 17761991
[No Abstract] [Full Text] [Related]
6. Current status of HER2 testing: caught between a rock and a hard place.
Schnitt SJ; Jacobs TW
Am J Clin Pathol; 2001 Dec; 116(6):806-10. PubMed ID: 11764067
[No Abstract] [Full Text] [Related]
7. Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials.
Press MF; Sauter G; Bernstein L; Villalobos IE; Mirlacher M; Zhou JY; Wardeh R; Li YT; Guzman R; Ma Y; Sullivan-Halley J; Santiago A; Park JM; Riva A; Slamon DJ
Clin Cancer Res; 2005 Sep; 11(18):6598-607. PubMed ID: 16166438
[TBL] [Abstract][Full Text] [Related]
8. Potential for HER-2/neu molecular targeted therapy for invasive bladder carcinoma: comparative study of immunohistochemistry and fluorescent in situ hybridization.
Matsubara H; Yamada Y; Naruse K; Nakamura K; Aoki S; Taki T; Tobiume M; Zennami K; Katsuda R; Honda N
Oncol Rep; 2008 Jan; 19(1):57-63. PubMed ID: 18097576
[TBL] [Abstract][Full Text] [Related]
9. Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma.
Santin AD; Bellone S; Van Stedum S; Bushen W; Palmieri M; Siegel ER; De Las Casas LE; Roman JJ; Burnett A; Pecorelli S
Cancer; 2005 Oct; 104(7):1391-7. PubMed ID: 16116605
[TBL] [Abstract][Full Text] [Related]
10. HER-2/neu analysis in breast cancer bone metastases.
Zustin J; Boddin K; Tsourlakis MC; Burandt E; Mirlacher M; Jaenicke F; Izbicki J; Ruether W; Rueger JM; Bokemeyer C; Simon R; Sauter G
J Clin Pathol; 2009 Jun; 62(6):542-6. PubMed ID: 19474354
[TBL] [Abstract][Full Text] [Related]
11. Does using a higher cutoff for the percentage of positive cells improve the specificity of HER-2 immunohistochemical analysis in breast carcinoma?
Hameed O; Chhieng DC; Adams AL
Am J Clin Pathol; 2007 Nov; 128(5):825-9. PubMed ID: 17951206
[TBL] [Abstract][Full Text] [Related]
12. Her-2/neu in barrett esophagus: a comparative study between histology, immunohistochemistry, and fluorescence in situ hybridization.
Rossi E; Villanacci V; Bassotti G; Casa DD; Missale G; Minelli L; Cestari R
Diagn Mol Pathol; 2006 Sep; 15(3):125-30. PubMed ID: 16932066
[TBL] [Abstract][Full Text] [Related]
13. HER-2/neu and p53 overexpression as biomarkers of breast carcinoma in women age 30 years and younger.
Maru D; Middleton LP; Wang S; Valero V; Sahin A
Cancer; 2005 Mar; 103(5):900-5. PubMed ID: 15643600
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of HER-2 gene status in gastric carcinoma using immunohistochemistry, fluorescence in situ hybridization, and real-time quantitative polymerase chain reaction.
Kim MA; Jung EJ; Lee HS; Lee HE; Jeon YK; Yang HK; Kim WH
Hum Pathol; 2007 Sep; 38(9):1386-93. PubMed ID: 17555797
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological relevance of HER2/neu and a related gene-protein cubic regression correlation in colorectal adenocarcinomas in Taiwan.
Li JW; Chuang TC; Yang AH; Hsu CK; Kao MC
Int J Oncol; 2005 Apr; 26(4):933-43. PubMed ID: 15753987
[TBL] [Abstract][Full Text] [Related]
16. Comparison of immunohistochemical and fluorescence in situ hybridization assessment of HER-2 status in routine practice.
Dolan M; Snover D
Am J Clin Pathol; 2005 May; 123(5):766-70. PubMed ID: 15981817
[TBL] [Abstract][Full Text] [Related]
17. Controversies in the assessment of HER-2: more questions than answers.
Leong TY; Leong AS
Adv Anat Pathol; 2006 Sep; 13(5):263-9. PubMed ID: 16998320
[TBL] [Abstract][Full Text] [Related]
18. Comparative analysis of c-erbB-2 (HER-2/neu) in squamous cell carcinoma of the tongue: does over-expression exist? And what is its correlation with traditional diagnostic parameters?
Angiero F; Sordo RD; Dessy E; Rossi E; Berenzi A; Stefani M; Sidoni A
J Oral Pathol Med; 2008 Mar; 37(3):145-50. PubMed ID: 18251938
[TBL] [Abstract][Full Text] [Related]
19. HER-2/neu expression in plasma and biopsy of patients with oral lichen planus in comparison to leukoplakia.
Guzzi G; Corsi MM; Pallotti F; La Porta CA; Spadari F
J Eur Acad Dermatol Venereol; 2006 Sep; 20(8):1027-8. PubMed ID: 16922972
[No Abstract] [Full Text] [Related]
20. Potential for molecular targeted therapy of HER-2/neu for invasive bladder cancer: examination of gene amplification by fluorescence in situ hybridization.
Yamada Y; Naruse K; Nakamura K; Aoki S; Taki T; Tobiume M; Zennami K; Katsuda R; Hirano M; Hayashida K; Mizumukai E; Nanaura H; Honda N
Oncol Rep; 2007 Nov; 18(5):1183-7. PubMed ID: 17914570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]